Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 42 of 58, showing 10 Applications out of 576 total, starting on record 411, ending on 420

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

411.

ECCT/17/09/02   WHO ACTION-I and ACTION-2 Trial
    A65913: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes       A65916: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes   
Principal Investigator(s)
1. Frederick Were
2. John Kinuthia
3. Zahida Parveen Qureshi
4. Zahida Parveen Qureshi
5. Zahida Parveen Qureshi
Site(s) in Kenya
1. Coast Provincial General Hospital (Mombasa Level 5 Hospital) (Mombasa county)
2. Kiambu Level 4 Hospital (Kiambu county)
3. Thika Level 5 Hospital (Kiambu county)
4. Nakuru Level 5 Hospital (Nakuru county)
 
30-04-2018 View

412.

ECCT/17/09/01   HPTN 084
    HPTN 084:   A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women         
Principal Investigator(s)
1. Samuel Gurrion Ouma
Site(s) in Kenya
KISUMU CRS
 
01-12-2017 View

413.

ECCT/17/08/09   A trial to compare two new combinations of antimalarial drugs with the standard combination of antimalarial drugs in Kenyan children
    An open-label randomised trial to assess the therapeutic efficacy and tolerability of arterolane-piperaquine plus single low dose primaquine versus arterolane-piperaquine plus mefloquine and single low dose primaquine versus artemether-lumefantrine plus single low dose primaquine in the treatment of uncomplicated falciparum malaria in children in Kenya.   
Principal Investigator(s)
1. Philip Bejon
Site(s) in Kenya
1. Kilifi County Hospital - Paediatric Out patient and Inpatient department (Kilifi county)
2. Pingilikani Dispensary (Kilifi county)
 
04-01-2018 View

414.

ECCT/17/08/07   Tambua Mapema Plus
    Impact of a novel HIV-1 RNA testing intervention to detect acute and prevalent HIV infection and reduce HIV transmission – Tambua Mapema Plus   
Principal Investigator(s)
1. Eduard J Sanders
2. Susan M Graham
Site(s) in Kenya
KEMRI Mtwapa Research Clinic
 
25-08-2017 View

415.

ECCT/17/08/06   Enhancing Preventive Therapy of Malaria In children with Sickle cell anemia in East Africa (EPiTOMISE)
    Enhancing Preventive Therapy of Malaria In children with Sickle cell anemia in East Africa (EPiTOMISE)   
Principal Investigator(s)
1. Festus Muigai Njuguna
Site(s) in Kenya
Homa Bay County Hospital
 
03-10-2017 View

416.

ECCT/17/08/05   Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection.
    Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection.   
Principal Investigator(s)
1. Isaac Tsikhutsu
Site(s) in Kenya
Kenya Medical Research Institute/Walter Reed Project HIV Program, Kericho
 
12-10-2017 View

417.

ECCT/17/08/04   P1081
    A PHASE IV RANDOMIZED TRIAL TO EVALUATE THE VIROLOGIC RESPONSE AND PHARMACOKINETICS OF TWO DIFFERENT POTENT REGIMENS IN HIV INFECTED WOMEN INITIATING TRIPLE ANTIRETROVIRAL REGIMENS BETWEEN 28 AND 36 WEEKS OF PREGNANCY FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION:    NICHD P1081   
Principal Investigator(s)
1. FREDRICK KIPYEGON SAWE
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed Project Clinical Research Centre.
 
13-11-2017 View

418.

ECCT/17/08/03   Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria
    A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria.           
Principal Investigator(s)
1. Grace Kiringa Kaguthi
Site(s) in Kenya
KEMRI Siaya
 
02-10-2017 View

419.

ECCT/17/08/02   IMPROVE (Improving PRegnancy Outcomes with intermittent PReVEntive treatment in Africa)
    IPTp with dihydroartemisinin-piperaquine and azithromycin for malaria, sexually transmitted and reproductive tract infections in pregnancy in high sulphadoxine-pyrimethamine resistance areas in Kenya, Malawi and Tanzania: an international multi-centre 3-arm placebo-controlled trial   
Principal Investigator(s)
1. Simon Kariuki
Site(s) in Kenya
1. Migori County Referral Hospital (Migori county)
2. Homa Bay County Referral Hospital (Homa Bay county)
3. Rongo Sub-County Hospital (Migori county)
4. Ahero Sub-County Hospital (Kisumu county)
5. Rabuor Sub-County Hospital (Kisumu county)
 
07-09-2017 View

420.

ECCT/17/08/01   A trial to compare the safety and immune response of the normal full and reduced doses of yellow fever vaccines in Kenyan adults
    A Phase IV randomized, double blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines.   
Principal Investigator(s)
1. Philip Bejon
Site(s) in Kenya
KEMRI Kilifi
 
07-09-2017 View